|
1
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patard JJ, Leray E, Rodriguez A,
Rioux-Leclercq N, Guillé F and Lobel B: Correlation between symptom
graduation, tumor characteristics and survival in renal cell
carcinoma. Eur Urol. 44:226–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang M, Gao H, Qu H, Li J, Liu K and Han
Z: MiR-137 suppresses tumor growth and metastasis in clear cell
renal cell carcinoma. Pharmacol Rep. 70:963–971. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keegan KA, Schupp CW, Chamie K, Hellenthal
NJ, Evans CP and Koppie TM: Histopathology of surgically treated
renal cell carcinoma: Survival differences by subtype and stage. J
Urol. 188:391–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Powles T, Staehler M, Ljungberg B,
Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M,
Kuczyk MA, et al: Updated EAU guidelines for clear cell renal
cancer patients who fail VEGF targeted therapy. Eur Urol. 69:4–6.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Berezikov E, Guryev V, van de Belt J,
Wienholds E, Plasterk RH and Cuppen E: Phylogenetic shadowing and
computational identification of human microRNA genes. Cell.
120:21–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zamore PD and Haley B: Ribo-gnome: The big
world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ying SY, Chang DC and Lin SL: The microRNA
(miRNA): Overview of the RNA genes that modulate gene function. Mol
Biotechnol. 38:257–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pfeffer SR, Yang CH and Pfeffer LM: The
Role of miR-21 in cancer. Drug Dev Res. 76:270–277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Quan J, Jin L, Pan X, He T and Lai Y, Chen
P, Lin C, Yang S, Zeng H and Lai Y: Oncogenic miR-23a-5p is
associated with cellular function in RCC. Mol Med Rep.
16:2309–2317. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan X, Quan J, Li Z, Zhao L, Zhou L,
Jinling X, Weijie X, Guan X, Li H, Yang S, et al: miR-566 functions
as an oncogene and a potential biomarker for prognosis in renal
cell carcinoma. Biomed Pharmacother. 102:718–727. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quan J, Li Y, Pan X, Lai Y, He T, Lin C,
Zhou L, Zhao L, Sun S, Ding Y, et al: Oncogenic miR-425-5p is
associated with cellular migration, proliferation and apoptosis in
renal cell carcinoma. Oncol Lett. 16:2175–2184. 2018.PubMed/NCBI
|
|
13
|
Fu H, Tie Y, Xu C, Zhang Z, Zhu J, Shi Y,
Jiang H, Sun Z and Zheng X: Identification of human fetal liver
miRNAs by a novel method. FEBS Lett. 579:3849–3854. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lang B and Zhao S: miR-486 functions as a
tumor suppressor in esophageal cancer by targeting CDK4/BCAS2.
Oncol Rep. 39:71–80. 2018.PubMed/NCBI
|
|
15
|
Gao ZJ, Yuan WD, Yuan JQ, Yuan K and Wang
Y: miR-486-5p functions as an oncogene by targeting PTEN in
non-small cell lung cancer. Pathol Res Pract. 214:700–705. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Fu J, Zhang Z and Qin H:
miR-486-5p regulates the migration and invasion of colorectal
cancer cells through targeting PIK3R1. Oncol Lett. 15:7243–7248.
2018.PubMed/NCBI
|
|
17
|
He M, Wang G, Jiang L, Qiu C, Li B, Wang J
and Fu Y: miR-486 suppresses the development of osteosarcoma by
regulating PKC-δ pathway. Int J Oncol. 50:1590–1600. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Behm-Ansmant I, Rehwinkel J and Izaurralde
E: MicroRNAs silence gene expression by repressing protein
expression and/or by promoting mRNA decay. Cold Spring Harb Symp
Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu F, Sang M, Meng L, Gu L, Liu S, Li J
and Geng C: miR-92b promotes autophagy and suppresses viability and
invasion in breast cancer by targeting EZH2. Int J Oncol.
53:1505–1515. 2018.PubMed/NCBI
|
|
22
|
Luo L, Xia L, Zha B, Zuo C, Deng D, Chen
M, Hu L, He Y, Dai F, Wu J, et al: miR-335-5p targeting ICAM-1
inhibits invasion and metastasis of thyroid cancer cells. Biomed
Pharmacother. 106:983–990. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Yang Y and Feng Z: Suppression of
microRNA-495 alleviates high-glucose-induced retinal ganglion cell
apoptosis by regulating Notch/PTEN/Akt signaling. Biomed
Pharmacother. 106:923–929. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao L, Wan Q, Li F and Tang CE: MiR-363
inhibits cisplatin chemoresistance of epithelial ovarian cancer by
regulating snail-induced epithelial-mesenchymal transition. BMB
Rep. 51:456–461. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bitarte N, Bandres E, Boni V, Zarate R,
Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM,
Fortes P and Garcia-Foncillas J: MicroRNA-451 is involved in the
self-renewal, tumorigenicity, and chemoresistance of colorectal
cancer stem cells. Stem Cells. 29:1661–1671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Zhang J, Xing C, Wei S, Guo N and
Wang Y: miR-486 inhibited osteosarcoma cells invasion and
epithelial-mesenchymal transition by targeting PIM1. Cancer
Biomark. 23:269–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Zhang T, Yang K, Zhang M and Wang
K: miR-486-5p suppresses prostate cancer metastasis by targeting
Snail and regulating epithelial-mesenchymal transition. OncoTargets
Ther. 9:6909–6914. 2016. View Article : Google Scholar
|
|
28
|
Shao Y, Shen YQ, Li YL, Liang C, Zhang BJ,
Lu SD, He YY, Wang P, Sun QL, Jin YX and Ma ZL: Direct repression
of the oncogene CDK4 by the tumor suppressor miR-486-5p in
non-small cell lung cancer. Oncotarget. 7:34011–34021. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goto K, Oue N, Shinmei S, Sentani K,
Sakamoto N, Naito Y, Hayashi T, Teishima J, Matsubara A and Yasui
W: Expression of miR-486 is a potential prognostic factor after
nephrectomy in advanced renal cell carcinoma. Mol Clin Oncol.
1:235–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang X, Du L, Duan W, Wang R, Yan K, Wang
L, Li J, Zheng G, Zhang X, Yang Y and Wang C: Serum microRNA
expression signatures as novel noninvasive biomarkers for
prediction and prognosis of muscle-invasive bladder cancer.
Oncotarget. 7:36733–36742. 2016.PubMed/NCBI
|
|
31
|
Ren C, Chen H, Han C, Fu D, Zhou L, Jin C,
Wang F, Wang D, Chen Y, Ma L, et al: miR-486-5p expression pattern
in esophageal squamous cell carcinoma, gastric cancer and its
prognostic value. Oncotarget. 7:15840–15853. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li C, Zheng X, Li W, Bai F, Lyu J and Meng
QH: Serum miR-486-5p as a diagnostic marker in cervical cancer:
With investigation of potential mechanisms. BMC Cancer. 18:612018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai
Y, Xiao L, Huang S, Chen L, Guo Z, et al: MicroRNA-486 as a
biomarker for early diagnosis and recurrence of non-small cell lung
cancer. PLoS One. 10:e01342202015. View Article : Google Scholar : PubMed/NCBI
|
